NCT02812056 - Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies | Biotech Hunter

Timeline

Start Date

September 30, 2016

Primary Completion Date

September 30, 2021

Conditions

Malignant Neoplasms of Digestive OrgansMalignant Neoplasms of Female Genital OrgansMalignant Neoplasms of Lip Oral Cavity and PharynxMalignant Neoplasms of Male Genital Organs

Interventions

DRUG

Alisertib

"Dose Escalation Phase:~Starting dose of Alisertib: 30 mg by mouth 2 times a day on Days 1 - 7 each 21 day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."

DRUG

TAK-228

"Dose Escalation Phase:~Starting dose of TAK-228: 1 mg by mouth daily Days 3 - 18, with the exception of 2 mg daily Days 3 - 7 and 10 - 14 schedule in a 21 day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."